Table 3.
Summary of Treatment‐Emergent Adverse Events (Occurring in n ≥2 Patients)
| TEAE, preferred term | Safety analysis set N = 13 |
|---|---|
| Any TEAE | 12 (92.3) |
| Events occurring in ≥2 patients | |
| Nasopharyngitis | 8 (61.5) |
| Contusion | 3 (23.1) |
| Eczema | 3 (23.1) |
| Fatigue | 3 (23.1) |
| Headache | 3 (23.1) |
| Arthralgia | 2 (15.4) |
| Cataract | 2 (15.4) |
| Constipation | 2 (15.4) |
| Cystitis | 2 (15.4) |
| Dizziness | 2 (15.4) |
| Herpes zoster | 2 (15.4) |
| Large intestine polyp | 2 (15.4) |
| Myalgia | 2 (15.4) |
| Nausea | 2 (15.4) |
| Rash | 2 (15.4) |
| Septic shock | 2 (15.4) |
| Tooth fracture | 2 (15.4) |
Data are shown as n (%).
TEAE = treatment‐emergent adverse event.